Investigational Drug Information for Entinostat
✉ Email this page to a colleague
What is the drug development status for Entinostat?
Entinostat is an investigational drug.
There have been 70 clinical trials for Entinostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 15th 2018.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Syndax Pharmaceuticals, and Merck Sharp & Dohme Corp.
There are four hundred and forty-four US patents protecting this investigational drug and zero international patents.
Summary for Entinostat
| US Patents | 444 |
| International Patents | 4,775 |
| US Patent Applications | 1,798 |
| WIPO Patent Applications | 1,152 |
| Japanese Patent Applications | 447 |
| Clinical Trial Progress | Phase 2 (2018-05-15) |
| Vendors | 68 |
Recent Clinical Trials for Entinostat
| Title | Sponsor | Phase |
|---|---|---|
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Entinostat
Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat
US Patents for Entinostat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Entinostat | ⤷ Subscribe | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | ⤷ Subscribe |
| Entinostat | ⤷ Subscribe | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Subscribe |
| Entinostat | ⤷ Subscribe | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Entinostat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Entinostat | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | ⤷ Subscribe |
| Entinostat | European Patent Office | EP3131552 | 2034-04-16 | ⤷ Subscribe |
| Entinostat | Spain | ES2823756 | 2034-04-16 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
